Please assess the completion status of the following clinical trial:

Trial Title: Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented Burkitt or atypical Burkitt according to World Health Organization (WHO) criteria.~* Pathology must be reviewed at the Brigham and Women's Hospital (BWH).~* Measurable or evaluable disease: Disease reproducibly measurable in two perpendicular dimensions on exam, computed tomography (CT), radiograph, or magnetic resonance imaging (MRI). Disease present on bone marrow biopsy will be considered as evaluable disease.~* The following may not be used as the sole site of measurable or evaluable disease: \*ascites, \*pleural effusion, \*bone lesion or \*central nervous system (CNS) disease.~* Age \> 18~* Laboratory data (within 2 weeks of study registration):~  * ANC \> 1500/ul;~ * platelet \> 100,000/ul;~ * creatinine \< 1.5 X normal;~ * creatinine clearance \> 60 ml/min;~ * bilirubin \< 1.5 X normal;~ * AST and ALT \< 2.5 X normal;~ * alkaline phosphates \< 3 X normal;~ * HIV negative;~ * cardiac ejection fraction \> 50%.~Exclusion Criteria:~* Previous chemotherapy or radiation therapy. Steroids of less than 72 hours duration for impending oncologic emergency are allowed.~* Uncontrolled bacterial, fungal, or viral infection.~* Concomitant malignancy excluding carcinoma in situ of the cervix and basal cell carcinoma of the skin.~* Serious comorbid disease. Clinically significant pulmonary symptomatology. In patients with a history of symptomatic pulmonary disease, pulmonary function tests (PFTs) should document an forced expiratory volume at 1 second (FeV1), forced vital capacity (FVC), and total lung capacity (TLC) of \> 60% predicted and carbon monoxide diffusing capacity of the lung (DLCO) of \> 50% predicted. No clinically significant cardiac symptomatology. The cardiac ejection fraction must be \> 50%.~* Pregnancy. All males and females with reproductive potential must consent to use an effective form of contraception while on study.~* Major surgery within the previous 2 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Risk (Type: EXPERIMENTAL): Low-risk patients receive 3 cycles of regimen A.~Regimen A:~Rituximab (375 mg/m\^2) on Days 1 and 3. Cyclophosphamide (800 mg/m\^2) on days 1 and 2. Vincristine (1.4 mg/m\^2) on days 1 and 10. Doxorubicin (50 mg/m\^2) on Day 1. Methotrexate (3000 mg/m\^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.~Leucovorin on days 11 and 12.~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles.
- High Risk (Type: EXPERIMENTAL): High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).~Regimen A (as described earlier).~Regimen B:~Rituximab (375mg/m\^2) on Day 1. Ifosfamide (1500mg/m\^2) on Days 1-5. Mesna (275 mg/m\^2) on Days 1-5. Etoposide (60mg/mg\^2) on Days 1-5. Cytarabine (2 gm/m\^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement).

Based on this trial design, predict the completion outcome and termination type (if applicable).